尼莫地平联合依达拉奉治疗蛛网膜下腔出血后脑血管痉挛的疗效观察

Effect of Nimodipine combined with Edaravone on Cerebral Vasospasm after Subarachnoid Hemorrhage

目的研究尼莫地平联合依达拉奉治疗蛛网膜下腔出血后脑血管痉挛的疗效。方法制定治疗方案A(基础治疗+依达拉奉),选取本院2019年9月-2020年9月收治的46例蛛网膜下腔出血患者,并视为对照组研究对象,并予以方案A治疗;制定治疗方案B(基础治疗+依达拉奉+尼莫地平),另选本院同期收治的46例蛛网膜下腔出血患者作为观察组研究对象,并予以方案B治疗;92例患者均伴有脑血管痉挛,发病时间不超过24h;对比两组患者采用不同方案治疗后的实际效果。结果①观察组治疗总有效率(97.83%)、NIHSS评分(7.31±2.54)、BI评分(81.96±9.87),均明显优于对照组,差异有统计学意义(P_(1)=0.0264,P_(2)=0.0021,P_(3)=0.0000);②观察组不良反应发生率(6.52%)与对照组(13.04%)相比,差异无统计学意义(P_(4)=0.2924)。结论方案B对蛛网膜下腔出血后脑血管痉挛的临床疗效更佳,可以有效修护患者脑神经组织,改善其日常生活能力,同时保障用药的安全性。

Objective To study the efficacy of Nimodipine combined with edaravone in the treatment of cerebral vasospasm after subarachnoid hemorrhage.Methods Treatment Protocol a(basic treatment+edaravone)was established in 46 patients with subarachnoid hemorrhage from September 2019 to September 2020,and treated as control group.Treatment Protocol B(basic treatment+edaravone+Nimodipine)was established,in addition,46 patients with cerebral vasospasm who were admitted to our hospital in the same period were selected as the observation group and treated with regimen B,92 patients were accompanied with cerebral vasospasm,the onset time was less than 24 hours;Two groups of patients with different treatment program after the actual effect.Results①The total effective rate(97.83%),NIHSS score(7.31±2.54)and BI score(81.96±9.87)in the observation group were significantly better than those in the control group(P_(1)=0.0264,P_(2)=0.0021,P_(3)=0.0000).②Compared with the control group(13.04%),the incidence of adverse reactions in the observation group(6.52%)was P_(4)=0.2924.There was no statistical significance.Conclusion Plan B is more effective in the treatment of cerebral vasospasm after subarachnoid hemorrhage.It can repair the cerebral nerve tissue,improve the ability of daily living and ensure the safety of medication.